<DOC>
	<DOCNO>NCT02183454</DOCNO>
	<brief_summary>To collect post marketing surveillance data patient receive least one Combo Bio-Engineered Sirolimus Eluting Stent use accord Instructions Use . Data collect order ass long term safety performance Combo Stent routine clinical practice .</brief_summary>
	<brief_title>MASCOT - Post Marketing Registry</brief_title>
	<detailed_description>The multicenter , multinational , prospective registry population consist patient undergo percutaneous coronary intervention ( PCI ) ( attempt ) placement least one Combo Stent ( accord Instructions use ) part routine clinical care . Approximately 2,500 patient 50 center Europe Asia enter registry . Patients enter registry follow one year . The registry consider finished patient complete 12 month follow-up . A follow-up scheduled 30 day , 6 month 12 month post procedure . Follow-up obtain plan regular visit outpatient clinic , telephone contact patient .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>In general , consecutive patient include registry . Patients exclude registration ANY follow condition apply : 1 . Undergoing PCI treatment stent thrombosis 2 . High probability nonadherence followup requirement ( due social , psychological medical reason ) 3 . Currently participate another investigational drug device study routine angiographic followup plan 4 . A life expectancy &lt; 12 month 5 . Explicit refusal participation registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>intracoronary stent</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>sirolimus</keyword>
	<keyword>endothelial progenitor cell</keyword>
</DOC>